Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Terminated 5

Sponsor Class

INDUSTRY 5NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × AEG 35156 × Clear all
NCT01018069 2011-07-13

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Aegera Therapeutics

Phase 2 Terminated
60 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT00558545 2009-12-02

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Aegera Therapeutics

Phase 1/2 Terminated
61 enrolled
Breast

Breast Neoplasms

NCT00557596 2009-12-01

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Aegera Therapeutics

Phase 1/2 Terminated
48 enrolled
Tumor-Agnostic

Carcinoma

NCT00558922 2009-07-30

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Aegera Therapeutics

Phase 1/2 Terminated
54 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00385775 2008-08-21

Study of XIAP Antisense for Advanced Cancers

Aegera Therapeutics

Phase 1 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡